Abstract: Techniques for transcribing and/or summarizing multimedia collaboration sessions are discussed herein. For example, users can communicate within a teleconferencing meeting associated with a channel. In some examples, a first machine learning model may be configured to receive audio-visual data and user interaction data (e.g., selected emojis, detected gestures, messages or text input by a user, a thread of messages, etc.) and output a teleconferencing meeting summary. In some examples, the teleconferencing meeting summary can include one or more highlights, action items, and/or artificial intelligence (AI) notes generated using a machine learning model(s).

Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

Abstract: Snippets of content associated with a communication platform are described. In an example, based at least in part on a determination, by the communication platform, that a user of the communication platform is permitted to access one or more snippets of content provided by one or more other users of the communication platform, causing one or more user interface elements associated with the one or more snippets of content to be presented via a user interface of a user computing device of the user. The communication platform can receive, from the user computing device, a request to view a snippet of content of the one or more snippets of content and can cause the snippet of content to be presented by the user computing device via the user interface associated with the communication platform.

Abstract: Various examples are directed to systems, methods, and apparatuses for providing an interactive developer interface of a group-based communication system. Various examples are directed to systems, methods, and apparatuses for consolidating application data associated with an application within a group-based communication interface. Various examples are directed to systems, methods, and apparatuses for indexing processing actions associated with a plurality of applications.

Abstract: A method for biomechanical motion tracking records accelerometer and rate gyroscope data from a single inertial measurement unit mounted on the sacrum of a runner. Recorded resultant linear acceleration measurements and recorded angular velocity measurements about the anterior-posterior axis are processed to identify right foot impact events and left foot impact events. Impact events are identified using crackle, the third derivative of the resultant linear acceleration measurements. Left and right impact events are distinguished using the angular velocity measurements.

Abstract: The present invention relates to pharmaceutical dry powder formulations, comprising (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (II) of formula (I-M-II) in combination with a lactose carrier, comprising lactose monohydrate as a mixture of coarse lactose and fine lactose, and to the process of manufacturing such pharmaceutical dry powder formulations and its application for use in the treatment of cardiopulmonary disorders, such as pulmonary arterial

Abstract: Functional diagnosis of a vehicle component of a vehicle in production involves a vehicle-external first computing unit generating a diagnosis execution protocol. The diagnosis execution protocol includes machine-readable instructions for performing an at least semi-automated functional diagnosis of vehicle components by an in-vehicle computing unit. The diagnosis execution protocol is transferred to the in-vehicle computing unit of the vehicle in production. The diagnosis execution protocol is executed by the in-vehicle computing unit. The in-vehicle computing unit controls a vehicle component to check for correct functioning of the vehicle component. The response behavior of the vehicle component is captured automatedly by the in-vehicle computing unit or with manual assistance by a person supervising the production of the vehicle. The captured response behavior is output to the first computing unit external to the vehicle or a second computing unit external to the vehicle.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The disclosure relates to a glass product or glass composition, and to a method of making a glass product. The glass composition can be manufactured without inhomogeneities in the glass melt and with sufficiently uniform and isotropic properties in the obtained products. The glass compositions further minimise and/or overcome the problem of blockage of pipes, liners, ducts or nozzles during the manufacture of high-quality glasses.

Abstract: The present invention provides, among other things, compositions and methods for reducing oxidation of a complex comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), for treating diseases and complications of prematurity. In some embodiments, the methods comprise adding antioxidants. In some embodiments, the antioxidants are methionine or sodium thiosulfate. In some aspects, the compositions provided are stable, pure and potent compositions comprising IGF-1 and IGFBP-3. In some aspects, the formulation is lyophilized.

Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(triflu-oromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl] [2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of car-diopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hyperten-sion (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pu

Abstract: Techniques for modifying data within a virtual space are discussed herein. A communication platform may receive a request from a user profile associated with a virtual space. The request may include instruction(s) for the communication platform to perform a modifying operation on data within a virtual space. Based on receiving the request, the communication platform may identify the data on which the operation is to be performed. The communication platform may input the data to one or more machine-learning models trained to output data that is a modified version of the data input to the machine-learning model (e.g., modified data). In such cases, the modified data may be modified consistent with the requested operation. The communication platform may receive the modified data from the machine-learning model and cause the modified data to be displayed via a user interface associated with the user profile.

Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 3-substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)azacycles of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and muscarinic receptor antagonists for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and P2X3 receptor antagonists for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of a muscarinic receptor antagonist and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular 2,3-Dihydrobenzo[b][1,4]dioxin-2-ylmethyl)piperazin-1-yl derivates of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and norepinephrine reuptake inhibitors for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.